# L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)

> **NCT07227350** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Philogen S.p.A.** · enrollment: 180 (estimated)

## Conditions studied

- Locally Advanced Basal Cell Carcinoma

## Interventions

- **DRUG:** L19IL2
- **DRUG:** L19TNF
- **DRUG:** L19IL2/L19TNF

## Key facts

- **NCT ID:** NCT07227350
- **Lead sponsor:** Philogen S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02
- **Primary completion:** 2031-02
- **Final completion:** 2031-02
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2026-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07227350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07227350, "L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07227350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*